MaxCyte, Inc.
General ticker "MXCT" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $279.5M (TTM average)
MaxCyte, Inc. does not follow the US Stock Market performance with the rate: -23.1%.
Estimated limits based on current volatility of 4.8%: low 0.76$, high 0.84$
Factors to consider:
- Total employees count: 114 (-20.3%) as of 2024
- US accounted for 66.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Insufficient funding, Regulatory and compliance, Acquisition/divestiture risks, Market competition, Manufacturing disruption and uninsured risks
- Current price 64.8% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.50$, 5.21$]
- 2025-12-31 to 2026-12-31 estimated range: [2.37$, 4.98$]
Financial Metrics affecting the MXCT estimates:
- Positive: with PPE of -10.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.35 <= 0.01
- Positive: Investing cash flow per share per price, % of 1.59 > -0.63
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
Short-term MXCT quotes
Long-term MXCT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $44.26MM | $41.29MM | $38.63MM |
| Operating Expenses | $71.62MM | $89.59MM | $89.82MM |
| Operating Income | $-27.36MM | $-48.30MM | $-51.20MM |
| Non-Operating Income | $7.58MM | $20.75MM | $10.14MM |
| Interest Expense | $0.13MM | $0.00MM | $0.00MM |
| R&D Expense | $19.51MM | $23.82MM | $22.23MM |
| Income(Loss) | $-19.78MM | $-27.55MM | $-41.05MM |
| Taxes | $3.79MM | $10.38MM | $0.00MM |
| Profit(Loss)* | $-23.57MM | $-37.92MM | $-41.05MM |
| Stockholders Equity | $253.97MM | $232.17MM | $206.25MM |
| Inventory | $8.58MM | $12.23MM | $8.91MM |
| Assets | $286.65MM | $268.27MM | $239.47MM |
| Operating Cash Flow | $-14.78MM | $-21.69MM | $-27.61MM |
| Capital expenditure | $18.48MM | $3.70MM | $1.65MM |
| Investing Cash Flow | $-24.82MM | $54.98MM | $6.93MM |
| Financing Cash Flow | $2.89MM | $2.14MM | $2.06MM |
| Earnings Per Share** | $-0.23 | $-0.37 | $-0.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.